Compare ADT Inc (ADT) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs Ascendis Pharma A/S — how do they compare? ADT Inc trades at $7.4 (market cap $5.44B), while Ascendis Pharma A/S trades at $252.45 (market cap $16.67B). The key difference: Ascendis Pharma A/S is far larger — about 3.1× ADT Inc's market cap, and ADT Inc pays a 2.95% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ADT | ASND | |
|---|---|---|
Market Cap | $5.44B | $16.67B |
Sector | Industrials | Health |
52-Week High | $8.85 | $277.18 |
52-Week Low | $6.30 | $189.74 |
Enterprise Value | $13.13B | $17.04B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.51, down 1.7% today, amid strong technical momentum with bullish moving averages and ADX signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.23 beating estimates of $0.22, and improving profitability with net margin reaching 11.86% in 2025. Recent news highlights ADT's Zacks upgrade to Buy and strong Q2 results with 18% operating cash flow growth.
ADT presents a compelling value opportunity with attractive valuation multiples (P/E 10.35, EV/EBITDA 4.93) and bullish analyst sentiment (47% Buy ratings). Key risks include high debt levels ($7.51B long-term debt) and competitive pressures in security services. The stock's technical strength and fundamental improvements support a positive near-term outlook, though investors should monitor debt management and industry competition.
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
